Principal Financial Group Inc Iveric Bio, Inc. Transaction History

Principal Financial Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	BUY	$26.24 - $39.63 $35,686 - $53,896	1,360 Added 4.27%	33,208 $1.31 Million
Q1 2023 May 09, 2023	SELL	$18.67 - $24.56 $34,670 - $45,607	-1,857 Reduced 5.51%	31,848 $774,000
Q4 2022 Feb 09, 2023	BUY	$17.24 - $23.95 $57,254 - $79,537	3,321 Added 10.93%	33,705 $721,000
Q3 2022 Nov 09, 2022	SELL	$9.4 - $18.59 $218,315 - $431,752	-23,225 Reduced 43.32%	30,384 $545,000
Q2 2022 Aug 10, 2022	BUY	$9.12 - $18.9 $276,071 - $572,121	30,271 Added 129.71%	53,609 $515,000
Q1 2022 May 09, 2022	SELL	$12.15 - $16.83 $12,247 - $16,964	-1,008 Reduced 4.14%	23,338 $392,000
Q4 2021 Feb 09, 2022	BUY	$13.83 - $18.78 $178,434 - $242,299	12,902 Added 112.74%	24,346 $407,000
Q3 2021 Nov 09, 2021	BUY	$7.07 - $17.5 $1,286 - $3,185	182 Added 1.62%	11,444 $186,000
Q2 2021 Aug 10, 2021	BUY	$5.69 - $7.17 $64,080 - $80,748	11,262 New	11,262 $71,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.